ShardaCare-Healthcity, the largest super speciality hospital in Greater Noida, has launched The Institute of Bone Marrow Transplant (BMT) to strengthen the treatment of complex blood disorders and expand access to advanced transplant care.
Experienced Leadership Strengthens the New Institute
Further reinforcing the initiative, Dr Pawan Kumar Singh, a leading haemato-oncologist and bone marrow transplant specialist in North India, has joined as Vice Chairman, Department of Haemato-Oncology & BMT. He is supported by Dr Isha, Associate Consultant, Department of Haemato-Oncology & BMT. Together, they will lead the clinical and academic direction of the Institute.
Comprehensive Care for Complex Blood Disorders
TAs reported by Pharmabiz, the Institute will treat a wide spectrum of conditions, including leukaemia, lymphoma, multiple myeloma, aplastic anaemia, bone marrow failure syndromes, thalassemia, and sickle cell disease. In addition, the centre will manage high-risk and complex transplant cases, offering integrated and specialised care.
Advanced Transplant Options for Children and Adults
Importantly, the BMT facility at ShardaCare–Healthcity will offer both paediatric and adult transplants. These include matched sibling, matched unrelated donor, and haploidentical (half-match) transplants. Moreover, the centre will provide autologous BMT for autoimmune diseases, particularly multiple sclerosis. Advanced capabilities will include high-dose and induction therapies, targeted and immunotherapies, graft manipulation, T-cell–depleted haploidentical transplants, and CAR-T cell therapy.
Addressing India’s Growing Burden of Blood Disorders
India is facing a silent health crisis driven by the rising burden of inherited blood disorders among both children and adults. Studies show that more than one in four children aged 0–12 years suspected of having a blood disorder are diagnosed with inherited haemoglobin disorders, with over half identified before the age of three. Meanwhile, many adults remain undiagnosed or develop long-term complications due to delayed detection. Across age groups, low awareness, late diagnosis, and limited access to specialised treatments such as BMT or immunosuppressive therapy continue to pose major challenges.
Advances in BMT Offer Curative Hope
However, advances in bone marrow transplantation and emerging gene therapies are rapidly transforming outcomes. These innovations now offer curative possibilities, reduce lifelong dependence on transfusions, and significantly improve quality of life for both paediatric and adult patients, the communication note stated.
Early Intervention Key to Better Outcomes
Highlighting the clinical perspective, Dr Pawan Kumar Singh said that blood disorders in India severely affect quality of life and survival across age groups, with adults often diagnosed late. Although BMT offers a potential cure, access remains limited due to donor shortages, high costs, and delayed referrals. He emphasised that in adults, earlier transplantation leads to significantly better outcomes. “The lack of proactive screening and timely intervention continues to burden thousands with preventable genetic conditions. Through this Institute, we aim to build a structured, ethical and patient-centric BMT ecosystem while strengthening early diagnosis, donor matching and access to advanced therapies,” he said.
Building a Sustainable and Inclusive Transplant Ecosystem
Echoing this vision, Dr Kousar Shah, Group CEO, ShardaCare-Healthcity, said the hospital is committed to developing a sustainable, high-quality transplant centre for both paediatric and adult patients. “By combining clinical expertise, global mentorship and community-focused initiatives, we aim to bridge gaps in access and bring hope to families who need these life-saving treatments the most,” he said.